| AZD7594 | AstraZeneca | Glucocorticoid receptor (GR) | Asthma | Ph 2 | EfficacyAZD7594 (later named velsecorat) reached a large Phase 2b dose-finding trial (GRANIT, ~805 patients) whose primary endpoint (change in FEV1 at week 12 versus placebo) was not statistically significant, despite dose-dependent trends on some measures. Although a 2022 review of the data concluded results could support a Phase 3 study, no Phase 3 trial has been registered and the molecule is absent from AstraZeneca's 2024-2025 respiratory pipeline communications, which instead highlight tezepelumab and tozorakimab. | source ↗ |
| AZD9567 | AstraZeneca | Glucocorticoid receptor (GR) | Rheumatoid Arthritis | Ph 2 | AZD9567, AstraZeneca's oral selective glucocorticoid receptor modulator, completed a Phase IIa head-to-head trial against prednisolone in active rheumatoid arthritis in November 2019 (results published in 2023). No rheumatoid arthritis trial has been registered for AZD9567 since then; the compound's only later trial (2020-2021) tested glycaemic effects in type 2 diabetes, not RA, and that too has had no follow-on activity in the years since. | source ↗ |
| mapracorat | Bayer | Glucocorticoid receptor (GR) | Atopic Dermatitis | Ph 2 | Mapracorat's (ZK245186/BOL-303242-X) atopic dermatitis trials all date from 2009-2013 and were sponsored by Bayer; no AD trial has been registered since. Bayer's and Bausch & Lomb's more recent mapracorat work is limited to an unrelated ophthalmic (cataract-surgery inflammation) formulation, not dermatitis. | source ↗ |
| PF-04171327 | Pfizer | Glucocorticoid receptor (GR) | Rheumatoid Arthritis | Ph 2 | PF-04171327, Pfizer's selective glucocorticoid receptor modulator, had its rheumatoid arthritis dose-comparison trial complete in 2014 with no positive continuation; no development activity in any indication has been recorded since. | source ↗ |
| AZD7594/abediterol | AstraZeneca | Glucocorticoid receptor (GR) | Asthma | Ph 1 | This is a fixed/free-combination formulation of AZD7594/velsecorat with abediterol tested only in an early Phase 1 disposition/PK study (completed ~2017). The lead AZD7594/velsecorat monotherapy program itself missed its Phase 2b primary endpoint and never advanced to Phase 3, and no continued combination-development activity has been found since. | source ↗ |